Methods for identifying substances that affect aging

JP2022547938A5Active Publication Date: 2024-11-07ZHEJIANG BAISHOUKANGDI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2022515528
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-09-09
Filing Date
2020-09-08
Publication Date
2024-11-07
Estimated Expiration
2040-09-08

AI Technical Summary

Technical Problem

Current methods for addressing aging are limited by the restricted use of longevity-associated genes like ApoE, Sirtl, and Foxo3, necessitating the discovery of new genes that can regulate aging processes effectively.

Method used

The method involves identifying substances that affect the activity and/or expression of the Zip11 gene, which is highly expressed in various organs and plays a role in inflammation, tumors, and metabolism, by determining their impact on Zip11 nucleic acid and protein levels, and using these substances to develop medicaments that can delay or improve aging.

Benefits of technology

Substances that increase Zip11 activity and/or expression can delay or ameliorate aging by improving physical and mental performance, while those that decrease Zip11 activity exacerbate aging, offering targeted interventions for aging-related conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000028_0000
    Figure 00000028_0000
  • Figure 00000028_0001
    Figure 00000028_0001
  • Figure 00000028_0002
    Figure 00000028_0002
Patent Text Reader

Abstract

A method for identifying a substance that can affect aging is provided, the method comprising determining the effect of a candidate substance on Zip11 activity and / or expression, and identifying a candidate substance that alters Zip11 activity and / or expression as a substance that can affect aging. Further provided is use of a substance that can increase Zip11 activity and / or expression in the preparation of a pharmaceutical product, wherein the pharmaceutical product is used for delaying or ameliorating aging.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present application relates to the field of biopharmaceuticals, and particularly to a method for identifying substances that can affect aging, wherein the substances are characterized in that they can affect the activity and / or expression of Zip11.

Background Art

[0002] Aging is an inevitable biological process, usually characterized by a decline in physiological functions that lead to morbidity and mortality, and this ongoing decline in physiological functions manifests as an overall decline in physical and mental abilities. Functional, tissue, and cellular aging are phenomena common to all multicellular organisms, but the rate at which aging occurs can vary significantly among individuals due to the combination of environmental and genetic factors. Although gene mutations in specific genes that are highly related to longevity and health, such as ApoE, Sirtl, Foxo3, Nrf3, etc., have been identified through whole-genome analysis of the human genome, there are problems with regional limitations, safety, and efficacy, and the use of these products is greatly restricted. Therefore, it is necessary to develop new longevity-related genes with excellent potential. (Reference: Zeng Y, etc. Sex Differences in Genetic Associations With Longevity, JAMA Netw Open. 2018 Aug ;l(4). Pii: el81670).

Disclosure of the Invention

Problems to be Solved by the Invention

[0003] Unexpectedly, the present application discovered the Zip11 gene, which encodes a member of Solute carrier family 39 (SLC39), which plays an important role in multiple regions such as inflammation, tumors, and metabolism, and is highly expressed in multiple organs such as the small intestine, stomach, genital organs, and liver. By controlling the expression of the Zip11 protein, it is possible to regulate related reactions that affect the degree of aging and lifespan of organisms, and the Zip11 gene is expected to be an excellent longevity-related gene. [Means for solving the problem]

[0004] The present invention provides a method for identifying substances that can affect aging, comprising determining the effect of a candidate substance on the activity and / or expression of Zip11, and identifying a candidate substance that causes such change in the activity and / or expression of Zip11 as a substance that can affect aging. The present invention also provides for using a substance that can increase the activity and / or expression of Zip11 for the preparation of a drug, the drug being used to delay or improve aging.

[0005] On the other hand, the present invention provides a method for identifying substances that can affect aging, the method comprising determining the effect of a candidate substance on the activity and / or expression of Zip11, and identifying a candidate substance that causes the aforementioned change in the activity and / or expression of Zip11 as a substance that can affect aging.

[0006] In some embodiments, determining the effect of a candidate substance on the activity and / or expression of Zip11 includes determining the effect of the candidate substance on the expression level and / or activity of the Zip11 nucleic acid.

[0007] In some embodiments, the nucleic acid expression level and / or activity of Zip11 is determined using a substance selected from the group consisting of a primer capable of specifically amplifying Zip11 and a nucleic acid probe capable of specifically recognizing Zip11.

[0008] In some embodiments, determining the effect of a candidate substance on the activity and / or expression of Zip11 includes determining the effect of the candidate substance on the expression level and / or activity of the Zip11 protein.

[0009] In some embodiments, the expression level and / or activity of the Zip11 protein is determined using a substance selected from the group consisting of reagents that specifically recognize the Zip11 protein and substances capable of measuring the activity of the Zip11 protein.

[0010] In some embodiments, candidate substances that result in increased activity and / or expression of Zip11 are identified as substances that can delay or improve aging.

[0011] In some embodiments, candidate substances that cause a decrease in the activity and / or expression of Zip11 are identified as substances that promote or worsen aging.

[0012] In some embodiments, the method includes administering the candidate substance to a non-human animal, organ, tissue and / or cell; determining the effect of the candidate substance on the activity and / or expression of Zip11 in the non-human animal, organ, tissue and / or cell; and identifying the candidate substance that causes an alteration in the activity and / or expression of Zip11 as a substance that affects aging.

[0013] In some embodiments, the method is in vitro or ex vivo.

[0014] In some embodiments, the aging state is determined by evaluating one or more of the following: physical morphology, hair condition, immune level, tumor condition, liver condition, spleen condition, reproductive capacity, motor capacity, longevity, and cognitive capacity.

[0015] In some embodiments, the body morphology is evaluated by detecting spinal morphology.

[0016] In some embodiments, the condition of the hair is evaluated by detecting hair loss.

[0017] In some embodiments, the state of the immune system is assessed by detecting cytokine levels.

[0018] In some embodiments, the state of the tumor is assessed by detecting tumor volume, tumor development, and / or the presence of tumor cells.

[0019] In some embodiments, the liver condition is assessed by detecting glutathione activity, glutathione activity, and / or liver / body weight ratio.

[0020] In some embodiments, the condition of the spleen is assessed by measuring the spleen relative to body weight.

[0021] In some embodiments, the fertility status is assessed by examining the percentage of fertile eggs.

[0022] In some embodiments, the mobility state is evaluated by the results of a fatigue-type baton turning test. In some embodiments, the longevity state is evaluated by detecting the survival time.

[0023] In some embodiments, cognitive state is assessed by an open-field test.

[0024] On the other hand, the present invention provides for the use of a substance that can increase the activity and / or expression of Zip11 for the preparation of a drug, which is used to delay or improve aging.

[0025] In some embodiments, the delay or improvement of aging comprises preventing or treating spinal curvature, preventing or treating hair loss, increasing cytokine levels, improving immunity, preventing or treating tumors, extending lifespan, preventing or treating liver damage, preventing or treating spleen damage, preventing or treating decreased reproductive capacity, improving athletic ability, and / or improving behavioral and cognitive abilities.

[0026] In some embodiments, the increase means that after administration of the substance, the activity and / or expression of Zip11 increases by at least 15-fold compared to the case where the substance is not administered.

[0027] In some embodiments, the activity and / or expression of Zip11 includes the activity and / or expression at the level of Zip11 nucleic acid and / or the level of Zip11 protein.

[0028] On the other hand, the present application provides a system for identifying a substance that can affect aging, which includes a substance capable of determining the effect of a candidate substance on the activity and / or expression of Zip11.

[0029] In some embodiments, the system includes a substance capable of determining the level and / or activity of the nucleic acid expression of Zip11.

[0030] In some embodiments, the substance capable of determining the level and / or activity of the nucleic acid expression of Zip11 is composed of a primer capable of specifically amplifying Zip11 and / or a probe capable of specifically recognizing Zip11.

[0031] In some embodiments, the system includes a substance capable of determining the expression level and / or activity of the protein of Zip11.

[0032] In some embodiments, the substance capable of determining the protein expression level and / or activity of Zip11 is composed of a reagent capable of specifically recognizing Zip11 protein and / or a reagent capable of determining the activity of Zip11 protein.

[0033] On the other hand, the present application also provides the use of a nucleic acid molecule encoding Zip11 or its expression product for the preparation of a drug, and the drug is used for delaying or improving aging.

[0034] In some embodiments, the delay or improvement of aging comprises preventing or treating spinal curvature, preventing or treating hair loss, increasing cytokine levels, improving immunity, preventing or treating tumors, extending lifespan, preventing or treating liver damage, preventing or treating spleen damage, preventing or treating decreased reproductive capacity, improving athletic ability, and / or improving behavioral and cognitive abilities.

[0035] In some embodiments, the nucleic acid molecule includes a nucleotide sequence represented by one of the SEQ ID No. 1s.

[0036] On the other hand, the present application also provides a method for delaying or improving aging, which involves administering an effective amount of a nucleic acid molecule encoding Zip11 or its expression product to a subject in need thereof.

[0037] In some embodiments, the delay or improvement of aging includes the prevention or treatment of spinal curvature, the prevention or treatment of hair loss, increased cytokine levels, improved immunity, the prevention or treatment of tumors, extension of lifespan, the prevention or treatment of liver damage, the prevention or treatment of spleen damage, the prevention or treatment of decreased reproductive capacity, improved athletic ability, the delay of the onset of decline in athletic ability, and / or improved behavioral and cognitive abilities.

[0038] In some embodiments, the nucleic acid molecule consists of the nucleotide sequence shown in SEQ ID No. 1.

[0039] On the other hand, the present application also provides a method for identifying the aging state of a subject, the method comprising measuring the Zip11 activity and / or expression of the subject.

[0040] In some embodiments, the Zip11 activity and / or expression includes Zip11 nucleic acid expression levels and / or activity, and / or Zip11 protein expression levels and / or activity.

[0041] In some embodiments, the level and / or activity of Zip11 nucleic acid expression in a subject is determined using a substance selected from the group consisting of primers that can specifically amplify Zip11 and nucleic acid probes that can specifically recognize Zip11.

[0042] In some embodiments, the protein expression level and / or activity of Zip11 in a subject is determined using a substance selected from the group consisting of reagents that specifically recognize the Zip11 protein and substances capable of measuring Zip11 protein activity.

[0043] In some embodiments, the state of aging is determined by evaluating one or more states from the following groups: physical morphological state, hair state, immune level state, tumor state, liver state, spleen state, reproductive capacity state, motor capacity state, longevity state, and cognitive capacity state.

[0044] In some embodiments, the body morphology is evaluated by detecting spinal morphology.

[0045] In some embodiments, the condition of the hair is evaluated by detecting hair loss.

[0046] In some embodiments, the state of the immune system is assessed by detecting cytokine levels.

[0047] In some embodiments, the state of the tumor is assessed by detecting tumor volume, tumor development, and / or the presence of tumor cells.

[0048] In some embodiments, the liver condition is assessed by detecting glutathione activity, glutathione activity, and / or liver / body weight ratio.

[0049] In some embodiments, the condition of the spleen is assessed by detecting the ratio of the spleen to body weight.

[0050] In some embodiments, the fertility status is assessed by examining the percentage of fertile eggs.

[0051] In some embodiments, the state of mobility is evaluated by the results of a fatigue-type baton turning test.

[0052] In some embodiments, longevity is assessed by detecting the duration of life.

[0053] In some embodiments, the cognitive state is evaluated by open-field experiments.

[0054] On the other hand, the present invention also provides the use of a substance for measuring Zip11 activity and / or expression in the preparation of a reagent, which is used to identify the aging state of a subject.

[0055] In some embodiments, the Zip11 activity and / or expression includes Zip11 nucleic acid expression levels and / or activity, and / or Zip11 protein expression levels and / or activity.

[0056] In some embodiments, the substance comprises a primer capable of amplifying Zip11, a nucleic acid probe capable of specifically recognizing Zip11, a reagent capable of specifically recognizing the Zip11 protein, and / or a substance capable of measuring the activity of the Zip11 protein.

[0057] In some embodiments, the state of aging is determined by evaluating one or more of the following conditions: physical morphological condition, hair condition, immune level, presence of tumors, liver condition, spleen condition, reproductive capacity, motor capacity, lifespan, and cognitive capacity.

[0058] In some embodiments, the body morphology is evaluated by detecting spinal morphology. In some embodiments, the hair condition is evaluated by detecting hair loss.

[0059] In some embodiments, the state of the immune system is assessed by detecting cytokine levels.

[0060] In some embodiments, the state of the tumor is assessed by detecting tumor volume, tumor development, and / or the presence of tumor cells.

[0061] In some embodiments, the liver condition is assessed by detecting glutathione activity, glutathione activity, and / or liver / body weight ratio.

[0062] In some embodiments, the condition of the spleen is assessed by measuring the spleen relative to body weight.

[0063] In some embodiments, the fertility status is assessed by examining the percentage of fertile eggs.

[0064] In some embodiments, the state of mobility is evaluated by the results of a fatigue baton test.

[0065] In some embodiments, longevity is assessed by detecting the duration of life.

[0066] In some embodiments, cognitive state is assessed by an open-field test.

[0067] On the other hand, this application provides a system for identifying the aging state of a subject, which includes a substance capable of measuring the expression and / or activity of Zip11.

[0068] In some embodiments, the system includes a substance that can determine the level and / or activity of nucleic acid expression in Zip 11.

[0069] In some embodiments, the substance capable of determining the level and / or activity of Zip11 nucleic acid expression includes: a primer capable of amplifying Zip11 and / or a nucleic acid probe capable of specifically identifying Zip11.

[0070] In some embodiments, the system includes a substance capable of determining the expression level and / or activity of the Zip11 protein.

[0071] In some embodiments, the substance capable of determining the expression level and / or activity of the Zip11 protein comprises a substance capable of specifically recognizing the Zip11 protein and / or a substance capable of determining the activity of the Zip11 protein.

[0072] In some embodiments, the state of aging is determined by evaluating one or more of the following conditions: physical morphological condition, hair condition, immune level, presence of tumors, liver condition, spleen condition, reproductive capacity, motor capacity, lifespan, and cognitive capacity.

[0073] In some embodiments, the body morphology is evaluated by detecting spinal morphology.

[0074] In some embodiments, the condition of the hair is evaluated by detecting hair loss.

[0075] In some embodiments, the state of the immune system is assessed by detecting cytokine levels.

[0076] In some embodiments, the state of the tumor is assessed by detecting the volume of the tumor.

[0077] In some embodiments, the liver condition is assessed by detecting glutathione activity, glutathione activity, and / or liver / body weight ratio.

[0078] In some embodiments, the condition of the spleen is assessed by measuring the spleen relative to body weight.

[0079] In some embodiments, the reproductive capacity is assessed by examining the fertilized egg ratio.

[0080] In some embodiments, the state of mobility is evaluated by the results of a fatigue-type baton turning test.

[0081] In some embodiments, longevity is assessed by detecting the duration of life.

[0082] In some embodiments, the cognitive state is evaluated by detecting absentee field tests.

[0083] On the other hand, the present application provides a method for evaluating the effect of a candidate substance on the aging state of a subject, the method comprising the following: 1) The step of administering the candidate substance to be evaluated to the subject; 2) A step of comparing the changes in Zip11 expression and / or activity in the subject before and after the administration; and 3) A step of evaluating the effect of the candidate substance on the aging state of the subject based on changes in the expression and / or activity of Zip11.

[0084] In some embodiments, the activity and / or expression of Zip11 includes activity and / or expression at the level of Zip11 nucleic acid and / or Zip11 protein.

[0085] In some embodiments, the candidate substance delays or improves the aging state of the subject if the expression of Zip11 is upregulated and / or its activity is enhanced in the subject after administration.

[0086] In some embodiments, the delay or improvement of aging includes the prevention or treatment of spinal curvature, the prevention or treatment of hair loss, increased cytokine levels, improved immunity, the prevention or treatment of tumors, extension of lifespan, the prevention or treatment of liver damage, the prevention or treatment of spleen damage, the prevention or treatment of decreased reproductive capacity, improved athletic ability, the delay of the onset of decline in athletic ability, and / or improved behavioral and cognitive abilities.

[0087] In some embodiments, the candidate substance accelerates or worsens the aging state of the subject if the expression and / or activity of Zip11 decreases in the subject after administration.

[0088] In some embodiments, the accelerated or worsened aging comprises worsening spinal curvature, worsening hair loss, decreased cytokine levels, decreased immunity, worsening or recurrence of tumors, shortened lifespan, worsening liver damage, worsening spleen damage, worsening fertility, decreased motor skills, and / or decreased behavioral and cognitive abilities.

[0089] In another embodiment, the present application also provides a non-human animal or a part thereof that overexpresses Zip11.

[0090] In some embodiments, the non-human animal or a portion thereof contains an additional number of Zip11 genes compared to the corresponding wild type.

[0091] In some embodiments, the Zip11 gene is expressed regulatoryally by a tissue-specific promoter.

[0092] In some embodiments, the additional copy number of the Zip11 gene is specifically expressed in the liver.

[0093] In some embodiments, the tissue-specific promoter comprises the nucleotide sequence shown in SEQ ID NO.1.

[0094] In some embodiments, the non-human animal or a portion thereof exhibits a phenotype that delays or improves the aging state.

[0095] In some embodiments, the delay or improvement of aging includes the prevention or treatment of spinal curvature, the prevention or treatment of hair loss, increased cytokine levels, improved immunity, the prevention or treatment of tumors, extension of lifespan, the prevention or treatment of liver damage, the prevention or treatment of spleen damage, the prevention or treatment of decreased reproductive capacity, improved athletic ability, the delay of the onset of decline in athletic ability, and / or improved behavioral and cognitive abilities.

[0096] In another embodiment, the present application also provides a non-human animal or a part thereof in which the expression and / or function of the Zip11 gene is disrupted.

[0097] In some embodiments, at least a portion of the Zip11 gene is knocked out.

[0098] In some embodiments, at least a portion of exon 5 of the Zip11 gene is knocked out.

[0099] In some embodiments, the non-human animals or parts thereof exhibit a phenotype of accelerated or aggravated aging.

[0100] In some embodiments, the accelerated or worsened aging comprises increased spinal curvature, increased hair loss, decreased cytokine levels, decreased immunity, worsening or recurrence of tumors, shortened lifespan, increased liver damage, increased spleen damage, decreased fertility, decreased motor function, and / or decreased behavioral and cognitive function.

[0101] Other aspects and advantages of this application will be readily apparent to those skilled in the art from the following detailed description. The following detailed description shows and describes only exemplary embodiments of this application. As those skilled in the art will recognize, the content of this application will enable those skilled in the art to make modifications to the specific embodiments disclosed without departing from the spirit and scope of the invention relating to this application. Accordingly, the drawings and description of this application are exemplary and not limiting. [Brief explanation of the drawing]

[0102] The specific features relating to this application are set forth in the attached claims. The features and advantages of the present invention covered by this application can be better understood by referring to the embodiments and drawings below. A brief description of the drawings is as follows.

[0103] [Figure 1A] This figure shows the results of comparing the sequences of human Zip 11 and zebrafish Zip 11. [Figure 1B] This figure shows the process for constructing the Zip11 knockout zebrafish described in the present invention. [Figure 2] This figure shows the morphological characteristics of the Zip11- / - zebrafish described in the present invention. [Figure 3] This figure shows the survival curve of the Zip11- / - zebrafish described in the present invention. [Figure 4] This figure shows the reproduction rate of the F2 generation of Zip11- / - zebrafish described in the present invention. [Figure 5] This figure shows the construction process of the Zip11- / - mouse model described in the present invention, where A is a schematic diagram of the knockout, B is the vector structure, and C is the Zip 11 mRNA level. [Figure 6-7] This figure shows the hair loss state of the Zip11- / - mouse described in the present invention. [Figure 8] This figure shows the hair loss and spleen condition of the Zip11- / - mouse described in the present invention. [Figure 9] This figure shows the state of a spleen section of a Zip11- / - mouse as described in the present invention. [Figure 10] This figure shows the state of a liver section of a Zip11- / - mouse as described in the present invention. [Figure 11] This figure shows the appearance and genotype electropherogram of the Zip11- / - mouse described in the present invention. [Figure 12] This figure shows the tumor growth state of Zip11- / - mice as described in the present invention. [Figure 13]This figure shows the amount of inflammatory factors secreted in Zip11- / - mice as described in the present invention. [Figure 14] This figure shows the motility of the Zip11- / - mouse described in the present invention. [Figure 15] This figure shows the construction process of the ZIP11 KI mouse model described in the present invention. [Figure 16] This shows the expression level of ZIP11 mRNA in wild-type mice during inflammation caused by knife beetle protein A. [Figure 17] This shows a comparison of liver (A), liver / body weight ratio (B), ALT (C), and AST (D) values ​​between wild-type mice and ZIP11 KI mice. [Figure 18] This image shows the morphology of liver cells from ZIP11 KI mice using different staining methods. [Figure 19] This study shows that vitamins increase the expression level of the ZIP11 gene in human-derived cells. [Figure 20] This shows the weight gain of Zip11- / - mice fed a high-fat diet. [Figure 21] This shows a decline in learning and cognitive abilities in male Zip11- / - mice. [Figure 22] This graph shows the trajectory of a mouse in an open-field experiment. [Figure 23] This shows an increase in p53 protein levels in Zip11- / - mice. [Figure 24] This shows a decrease in M1 macrophages (A) and an increase in M2 macrophages (B) in Zip11- / - mice after LPS stimulation. [Figure 25] This shows a decrease in bilirubin in mice that overexpress ZIP11. [Figure 26] This shows elevated bilirubin levels in Zip11- / - mice. [Modes for carrying out the invention]

[0104] The specific embodiments described below illustrate how the present application is carried out, and other advantages and effects of the present application can be easily understood by those skilled in the art, as disclosed herein.

[0105] Zip11 nucleic acid, Zip11 protein

[0106] In this application, the terms "Zip11," "Zip11," "ZIP11," and "SLC39A11" are used interchangeably and generally refer to a member of Solute carrier protein family 39 (SLC39). They may also refer to the gene encoding the Zip11 protein. The Zip11 described herein may include human Zip11, zebrafish Zip11 / or mouse Zip11, or functional fragments or variants thereof, or homologs in other species.

[0107] For example, human ZIP11 may consist of a 342-amino acid fragment, and its amino acid sequence can be found at NCBI accession number NP_001153242.1, coded by the NCBI database Gene ID.201266; zebrafish Zip11 protein may contain a 123-amino acid fragment, and its amino acid sequence can be found at NCBI accession number XP_021335877.1, and the zebrafish Zip11 gene sequence can be found at NCBI accession number NC_007123.7; mouse Zip11 may contain a 342-amino acid fragment, and its amino acid sequence is at NCBI accession number NP_001159975.1; the mouse Zip11 gene is listed in the MGI database ID:1917056.In this application, Zip11 knockout may be denoted as Zip11 KO or Zip11- / -. Knock-in or overexpression of Zip11 can be denoted as ZIP11 KI or ZIP11 KI.

[0108] The inventors of this invention compared the genomes of 2,178 centenarians (564 men and 1,614 women) and 2,299 middle-aged control subjects (773 men and 1,526 women) using genome-wide association analysis and discovered several sequence mutations and single nucleotide polymorphisms (SNPs) in both men and women that were significantly associated with longevity (p<10⁵). In men, several SNP genes, including ZIP11, were found to be significantly associated with aging (Zeng Y, etc. Sex Differences in Genetic Associations With Longevity, JAMA Netw Open. 2018 Aug;l(4).pii: el81670).

[0109] aging phenomenon

[0110] In this application, "aging" generally refers to the accumulation of changes that occur in a living organism over time. Such changes are diverse, ranging from those that affect the function of genes and cells to those that affect the function of organs, organ systems, and the organism as a whole. In particular, aging is a change that occurs after an organism has reached biological maturity and can progress until the organism ultimately dies. The state of aging can be judged by evaluating a group of conditions such as physical morphology, hair condition, immune level, tumor condition, liver condition, spleen condition, reproductive capacity, motor capacity, lifespan, and cognitive capacity.

[0111] The inventors of the present invention have found that aging is delayed or improved in individuals in whom Zip11 activity and / or expression is increased. "Delayed or improved" generally means preventing or treating by reducing, minimizing or eliminating the progression of a condition, disease, disorder or phenotype (including abnormalities or symptoms). The term delaying or improving aging includes preventing or treating spinal curvature, preventing or treating hair loss, increasing cytokine levels, improving immunity, preventing or treating tumors, extending lifespan, preventing or treating liver damage, preventing or treating spleen damage, preventing or treating fertility decline, enhancing athletic ability and / or delaying the point at which athletic ability declines, and / or enhancing behavioral cognitive ability. The prevention or treatment of spinal curvature may include reducing the degree of spinal curvature or correcting the spine. The prevention or treatment of hair loss may consist of reducing the degree of hair loss or being hairless. The cytokines may consist of IL-6, IL-2, IL-1-β, IL-7, IL-10, IL-12, TNF-α, IFN-α, IFN-β, IFN-γ, GM-CSF, and G-CSF. The enhancement of immunity may include increasing cytokine levels. The enhancement of immunity may include increasing the proportion of M1 macrophages and decreasing the proportion of M2 macrophages. The prevention or treatment of tumors may include reducing tumor size or preventing tumor development. The extension of lifespan may include reducing the activity / expression levels of aging-related genes. The extension of lifespan may include extending survival time or increasing population survival. The prevention or treatment of liver damage may include improving susceptibility to hepatitis, for example, susceptibility to hepatitis can be assessed based on glutathione and glutathione levels, as well as hepatocyte morphology. The prevention or treatment of decreased fertility may include increasing the proportion of fertile fertilized eggs. Improvements in motor skills may include extending the time spent performing physical activities and delaying the point at which motor skills decline. Improvements in cognitive abilities may include an increased desire to explore unfamiliar spaces (such as open-field experiments).

[0112] Furthermore, the inventors of the present invention have found that aging is accelerated or worsened in individuals with reduced Zip11 activity and / or expression. "Accelerated or worsened" generally means an increase, enhancement, or maintenance of a condition, disease, disorder, or phenotype (including abnormalities or symptoms). Accelerated or worsened aging includes accelerated or worsened spinal curvature, accelerated or worsened hair loss, decreased cytokines, decreased immunity, accelerated or worsened tumors, shortened lifespan, accelerated or worsened liver damage, accelerated or worsened spleen damage, decreased reproductive function, decreased motor skills, and / or decreased cognitive abilities. The accelerated or worsened spinal curvature may include an increase in the degree of spinal curvature. The accelerated or worsened hair loss may include abnormal or complete hair loss of scalp or body hair. Examples of cytokines include IL-6, IL-2, IL-1-β, IL-7, IL-10, IL-12, TNF-α, IFN-α, IFN-β, IFN-Γ, GM-CSF, and G-CSF. The weakening of immunity may include a decrease in cytokine levels. The weakening of immunity may include a decrease in the proportion of M1 macrophages and an increase in the proportion of M2 macrophages. The acceleration or worsening of tumors may include an increase in tumor size. The reduction in lifespan may include a reduction in survival time or a reduction in quiet population survival rate. The acceleration or worsening of liver damage may constitute hepatomegaly. The accelerated or worsened splenic damage may include splenomegaly. The acceleration or worsening of fertility may include a decrease in the proportion of fertilizable eggs. The decline in motor skills may include a reduction in the time it takes to maintain motor skills or an earlier onset of decline in motor skills. The decline in cognitive abilities may include a decrease in the desire to explore unfamiliar spaces (e.g., open-field experiments).

[0113] The changes in Zip11 activity and / or expression can be measured using methods well known to those skilled in the art, such as immunohistochemistry, PCR, RT-PCR, in situ hybridization, Southern blotting, Western blotting, Northern blotting, spectrophotography, gene chips, flow cytometry (FACS), protein microarrays, DNA sequencing, and ELISA. In some embodiments, the method may include a primer capable of specifically amplifying Zip 11 and a nucleic acid probe capable of specifically recognizing Zip 11. The probe may specifically bind to a particular site on the Zip11 gene and not to genes other than Zip11, thereby "specifically identifying" the Zip11 gene, and the probe carries a detectable signal. The primer amplifies the Zip11 gene and not other genes, i.e., "specific amplification." In some embodiments, the candidate consists of oligonucleotide fragments. Such fragments need to be long enough to hybridize with RNA or DNA in the sample. The number of nucleotides may be 10-40 or more, for example, 45, 50, 100, 500, or up to the full length. In some cases, the method may include a reagent that specifically recognizes the Zip11 protein and a substance that can measure the activity of the Zip11 protein. The substance may be a protein-binding molecule such as an antibody or ligand that specifically binds to Zip11 or its protein fragments.

[0114] Applications, methods, systems

[0115] This application provides a method for identifying substances that can affect aging, the method of which may include determining the effect of a candidate substance on activity and / or expression, and identifying a candidate substance that alters such activity and / or expression as a substance that can affect aging. In some embodiments, the method may be used for drug screening. For example, a substance that increases the activity and / or expression of Zip11 may be identified as a substance that can affect aging, a drug may be prepared using the substance, and the drug may be used to delay or improve aging. For example, if a substance that decreases the activity and / or expression of Zip11 is identified as a substance that can increase the activity and / or expression of Zip11 as a substance that affects aging, the substance may have toxic side effects.

[0116] This application provides a system for identifying substances that can affect aging, the system may include substances that can determine the effect of a candidate substance on the activity and / or expression of Zip11. The system may also consist of a kit, which may include the substances that can affect aging as described in this application in appropriate packaging and may include written materials such as instructions for use, a review of clinical trials, and a list of side effects. Such a kit may also include information that demonstrates or confirms the activity and / or benefits of the composition, such as scientific literature, package inserts, clinical trial results, and / or summaries thereof, and / or reference literature describing the method of administration, administration, side effects, drug interactions, or other information useful to healthcare professionals. The kit may further include another drug. In some cases, the substances that can affect aging and the drug may be provided as a separate composition in a separate container within the kit. In some cases, the substances that can affect aging and the drug may be provided as a single composition in a container of the kit. Appropriate packaging and additional items (e.g., measuring cups for liquid formulations, foil packaging to minimize exposure to air, etc.) are known in the art and may be included in the kit. In some cases, the system may be provided, sold, and / or marketed to stakeholders, including healthcare providers, physicians, nurses, pharmacists, prescribers, drug developers, and drug manufacturers. In other cases, the system may be sold directly to consumers.

[0117] This application provides for the use of a nucleic acid molecule encoding Zip11 or an expression product thereof for the preparation of a drug, which is used to delay or improve aging. In some embodiments, the nucleic acid molecule encoding Zip11 or an expression product thereof may be used for the preparation of a drug for gene therapy. The drug may include a vector capable of expressing the nucleic acid molecule. The vector may be a nucleic acid molecule capable of growing another nucleic acid to which it is bound. This also includes vectors that function as self-replicating nucleic acid structures, and vectors that are incorporated into the genome of a host cell into which the vector has been introduced. Certain types of vectors can induce the expression of nucleic acids operably linked thereto. Examples of the drug include substances that act on the promoter or enhancer region of Zip11 to promote its expression, substances that promote the transcription of the Zip11 gene to mRNA, or substances that exert a similar effect with the help of, for example, intracellular transcription factors. The drug may also consist of a container that can be placed together with packaging materials that describe how to use these drugs. Generally, these instructions include definitive descriptions of the drug concentration and, in some embodiments, may include relative amounts of excipient components or diluents (e.g., water, saline, or PBS) necessary to reconstitute the pharmaceutical composition.

[0118] The present application also provides a method for delaying or improving aging, comprising administering an effective amount of a nucleic acid molecule encoding Zip11 or an expression product thereof to a subject in need. For the purposes of this application, the term “subject” generally refers to any person or non-human animal. Non-human animals refer to all vertebrates, including mammals and non-mammals, such as non-human primates, sheep, dogs, cats, cattle, horses, chickens, fish, mice, rabbits, amphibians, and reptiles.

[0119] For the purposes of this application, the term “effective dose” generally means an amount of an agent that is non-toxic but sufficient to produce a desired biological result. The amount is sufficient to reduce and / or improve the severity and / or duration of a condition (symptoms or related conditions of aging), to prevent the worsening of the condition, to cause a decline in the condition, to prevent the recurrence, onset or onset of one or more symptoms related to the condition, or to enhance or improve the preventive or therapeutic effect of another treatment (e.g., a prophylactic or therapeutic agent). For example, an effective dose may be an amount that slows or improves aging.

[0120] In the context of this application, the term “administration” generally refers to a method of administering a dosage of a substance or pharmaceutical composition to a subject (e.g., a patient with symptoms of aging). Administration may be carried out by any suitable means, including but not limited to injection (subcutaneous, intravenous, parenteral, intraperitoneal, intrathecal, etc.), oral, inhalation, rectal, and intradermal.

[0121] For example, the substance described herein that increases the activity and / or expression of Zip11, the nucleic acid molecule encoding Zip11 or its expression product, and the vector can be prepared separately or together in a form suitable for oral administration. For example, tablets or capsules prepared by conventional means with the addition of pharmaceutically acceptable excipients such as binding reagents, fillers, lubricants, disintegrants, or wetting agents. Methods for encapsulating tablets are known to those skilled in the art. For oral administration, the preparation of liquids can take the form of solutions, syrups, or suspensions, or they can be provided in the form of dry products composed with water or other suitable excipient carriers before use. Various delivery systems are known and can be used to administer the compounds of the present invention, including encapsulation into liposomes, particles, microcapsules, recombinant cells capable of expressing the compounds, receptor-mediated cell division, and the construction of nucleic acids as part of retroviruses or other vectors.

[0122] In some embodiments, nucleic acid molecules containing a nucleic acid encoding Zip11 or an expression product thereof may be administered by gene therapy methods to treat, suppress, or prevent diseases or disorders associated with abnormal expression and / or activity of Zip11. Gene therapy is a treatment that involves administering an expressed or expressible nucleic acid to a subject. The nucleic acid molecules described in this application produce proteins that mediate the therapeutic effect thereby encoded. For example, the Zip11 activity and / or expression of the encoding nucleic acid molecule or its expression product may be increased after administration to a subject requiring it.

[0123] This application provides a method for identifying the aging status of a subject, comprising measuring the activity and / or expression of Zip11 in the subject using a substance capable of measuring the activity and / or expression of Zip11 or a reagent prepared from such substance, comparing the Zip11 activity and / or expression with standard activity and / or expression, thereby determining an increase or decrease in the activity or expression of the Zip11 gene. In some embodiments, the method may be used in diagnostic / medical tests, for example, by a practicing physician to determine the aging status of a subject based on Zip11 activity and / or expression in the subject. In some cases, the method described may be used in research, for example, to evaluate the effect of a candidate substance on the aging status of a subject. In some cases, the method described may also be used in pharmaceutical processes, such as identifying substances to be screened for their effects on aging status. In some cases, the method may also be used in diagnostic / medical processes, for example, to identify the aging status of a subject.

[0124] This application provides for the use of a substance for determining Zip11 activity and / or expression for the preparation of reagents used to identify the aging status of a subject. In some cases, reagents capable of detecting Zip11 expression / activity can be prepared and used for diagnostic and / or medical testing.

[0125] This application provides a system for identifying the aging status of a subject, comprising a substance capable of measuring the expression and / or activity of Zip11. In some embodiments, the system may be provided, sold, and / or marketed to stakeholders, including healthcare providers, physicians, nurses, pharmacists, prescribers, drug developers, and drug manufacturers. It may also be sold directly to consumers.

[0126] Furthermore, this application provides a method for evaluating the effect of a candidate substance on the aging state of a subject. In some cases, the method can be used for drug screening. For example, by administering the candidate substance to be evaluated to a subject and comparing the expression and / or activity of Zip11 in the subject before and after administration, if the expression and / or activity of Zip11 increases, the candidate substance can be used in the preparation of an anti-aging drug as a substance that can delay or improve aging. In addition, the described method can be used to evaluate the safety of the candidate substance. For example, by administering the candidate substance to a subject and comparing the changes in the expression and / or activity of Zip11 in the subject before and after administration, if the expression and / or activity of Zip11 decreases to the extent that the substance promotes or worsens aging toxicity, it can be determined that the candidate substance is an aging toxicity promoting substance.

[0127] Animals other than humans or parts thereof

[0128] This application provides a non-human animal or a portion thereof that overexpresses Zip11. In this application, the term “overexpression” generally means a gene that is transcribed or translated at a detectably high level on the corresponding cell compared to normal cells of the same tissue type.

[0129] Therefore, overexpression can refer to the overexpression of proteins or RNA (due to transcription, post-transcriptional processing, translation, post-translational processing, changes in stability, changes in proteolysis), localized overexpression (increased nuclear localization), and improved functional activity due to changes in protein transport patterns. For example, overexpression may refer to an increase in expression levels of 100%, 150%, 200%, 250%, 300%, 400%, 500%, or more compared to normal or control cells. Such overexpression can be achieved by methods known in the art. For example, it can be achieved by means of introducing a foreign gene. For example, the Zip11 gene can be overexpressed by introducing it into the genome of a non-human animal using a vector containing a promoter. The promoter may be a strong CAG promoter. The vector can be any vector available for genetic engineering, such as plasmid vectors, viral vectors, mucosal vectors, bacterial artificial chromosomes (BACs), yeast artificial chromosomes (YACs), and non-plasmid vectors, and has the function of inserting a target gene into the target gene region of the host by homologous recombination. In some embodiments, sgRNAs targeting the mouse H11 locus can be constructed using Cas9 / RNA system gene targeting technology. In this application, the term "H11" generally refers to the proliferation of a motif that allows for the insertion of a potent exogenous promoter to drive higher expression. In other cases, a vector containing the CAG-Loxp-Stop-Loxp-hZ / P7J-P2A-tdTomato fragment can be simultaneously constructed and co-injected with Cas9, after which the DNA strand is cleaved by Cas9, and the CAG-Loxp-Stop-Loxp-hZ / P7J-P2A-tdTomato fragment can be recombined at the target site by homologous recombination. The host cells into which the knock-in vector is introduced are cells of the non-human animal or cells (including cell clusters) capable of differentiating into the non-human animal cells. Various cells can be used as such host cells, depending on the purpose, such as pluripotent stem cells such as ES cells and iPS cells, germline stem cells such as spermatogonial stem cells capable of differentiating into germ cells, and fertilized eggs.The knock-in vector can be introduced into the host cells by known methods such as electroporation. A chimeric animal can be obtained by injecting the pluripotent stem cells into an early embryo using known methods such as microinjection and transplanting them into a surrogate mother for development. Alternatively, individuals from which the knock-in array has been purified can be obtained from the offspring by mating the chimeric animals.

[0130] Non-human animals or components that overexpress the ZIP11 gene as described herein (e.g., ZIP 11 KI mice) exhibit increased ZIP11 activity and / or expression, increased sensitivity to immune stimuli (e.g., in knife bean protein-induced liver injury, ZIP 11 KI mice show at least four-fold, e.g., four-fold, five-fold, six-fold or more, increases in glutaminase and glutathione levels compared to wild-type mice) and / or greater resistance to age-related diseases. Non-human animals or components that overexpress the ZIP 11 gene as described may exhibit tumor reduction or delay. For example, female Zip11- / - mice, also suffering from tumors, have larger tumor volumes compared to wild-type mice.

[0131] Furthermore, this application provides a non-human animal or a part thereof, which may be a rodent or a fish. For example, it may be a mouse. The expression and / or function of the Zip11 gene may be disrupted in the said non-human animal or a part thereof. In this application, the term “disrupted” generally means that the gene is not expressed and / or loses its function as an expression product. It is conceivable that the disrupted gene is not expressed or cannot direct the efficient expression of an expression product by structurally disrupting the gene (e.g., by insertion of an Flp / FRT element or a Cre / Loxp element) such that the gene contains at least one mutation or structural change. Such disruption can be achieved by knocking out at least a part of the Zip11 gene. The knockout can be constructed by any method known in the art.

[0132] In some cases, this can be achieved with the help of a Crisper / Cas9 system construct. Specifically, it is possible to obtain a model mouse in which the expression and / or function of the Zip11 gene is disrupted by crossing a Zip11 allele mouse possessing the Flox locus with a tool mouse that specifically expresses Cre. It is also possible to knock out a target gene using the principle of homologous recombination. For example, the Slc39all gene can be Flox-modified using embryonic stem cell targeting. In some cases, at least a portion of exon 5 of the Zip11 gene is knocked out. For example, the non-human animal or a portion thereof may be a mouse model in which the Zip11 gene is knocked out. Here, "disrupted" means that the activity and / or expression of Zip11 is significantly reduced compared to the wild type in which the Zip11 gene is not knocked out.

[0133] Non-human animals or sites in which the expression and / or function of the Zip11 gene described in this specification are disrupted will show reduced Zip11 activity and / or expression, and accelerated or worsened senescence phenotypes. For example, in Zip11 KO zebrafish models, female fertilized eggs at 6-12 months of age show a decrease in reproductive rate of approximately 10% to 100% (e.g., approximately 20% to 90%, 30% to 80%, 40% to 70%, or 50% to 60%), male fertilized eggs at 0-3 months of age show a decrease of approximately 10% to 100% (e.g., approximately 20% to 80%, 30% to 70%, 30% to 60%, or 40% to 50%), and males at 6-12 months of age show a decrease in reproductive rate of less than 1%. For example, in Zip11 knockout zebrafish, the survival rate of females at 10 months of age is 85% and the survival rate of males is only 25%, compared to wild-type zebrafish. For example, mice with Zip11 knocked out can have their motor skills reduced by at least 30% (e.g., at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more).

[0134] In some embodiments, the non-human animal or part thereof may be used in studies such as evaluating the effect of a candidate substance on Zip11 activity and / or expression levels. In some embodiments, the non-human animal or site may be used in pharmaceutical processes such as screening for and identifying substances that affect Zip11 activity and / or expression. In some embodiments, the non-human animal or site may be used in diagnostic and / or medical testing processes such as identifying the aging state of a subject. In some cases, the non-human animal or part thereof may be provided, sold, and / or marketed to stakeholders such as researchers, sales representatives, and pharmaceutical personnel.

[0135] In this application, the term “includes” usually refers to including a clearly specified feature but not excluding other elements.

[0136] In this application, "approximately" generally means a range of 0.5% to 10% of a specified value, for example, 0.5%, 1%, 1.5%, 2%, 2.5%, 3%, 3.5%, 4%, 4.5%, 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, or 10% above or below.

[0137] The following examples are not intended to be limited to theory, but are used solely to illustrate the fusion protein, preparation method, and uses of this application, and are not intended to limit the scope of this application.

[0138] Examples

[0139] Example 1: Construction of a zebrafish Zip11 knockout (KO) model

[0140] For the zebrafish gene (sequence available in the NCBI database Gene ID: 101882215), sgRNA was designed and its sequence is shown in SEQ ID NO:4. The pT7-gRNA plasmid was used as a PCR template, the gRNA template was purified by gum cutting, and in vitro transcription was performed using the T7 kit. The transcription of sgRNA was confirmed by 1% agarose gel electrophoresis, and a stock gRNA solution suitable for microinjection was obtained by isoamyl alcohol extraction and purification using phenol chloroform. The pXT7-Cas9 plasmid was linearized with the restriction enzyme Xbal, and after confirming the completion of linearization by agarose gel electrophoresis, column purification was performed using the T7 kit, and Cas9 mRNA was used as an in vitro transcription template. GRNA was purified by agarose gel electrophoresis to obtain a stock Cas9 mRNA solution for microinjection. sgRNA and Cas9-mRNA were mixed at appropriate concentrations and injected into zebrafish fertilized eggs by microinjection, with uninjected wild-type zebrafish embryos used as controls. Incubation was performed to obtain the F0 generation of Zip knockout zebrafish. Figure 1A shows the results of a comparison of the amino acid sequences of Zip11 in humans and zebrafish, and Figure 1B shows the location of the Cas / gRNA target site in the Zip11 gene of the knockout zebrafish.

[0141] Example 2: Zip11 KO Zebrafish Model Aging Phenotype

[0142] The F0 generation of male and female zebrafish were crossed to produce the F1 generation of pure zebrafish (Zip11- / -), and the F1 generation was crossed to produce the F2 generation of Zip11- / - mutants. These were cultured, and their phenotypes were observed and recorded. The results are shown in Figure 2. Sequential comparative observation of Zip11 knockout and wild-type zebrafish revealed that 1.5-year-old F1 generation females had curved spines. Both male and female zebrafish of the F2 generation had curved spines and thin, degenerated fins, while the wild-type fins were intact.

[0143] The survival rates of the F2 generation and wild-type zebrafish from 3 to 24 months of age were recorded, and survival curves were plotted. As shown in Figure 3, the survival rate of the Zip11- / -F2 generation from birth to 6 months of age was similar to that of wild-type zebrafish. From 6 months of age, the male F2 generation showed a high mortality rate, and all died by 16 months of age. Death was confirmed in the female F2 generation at 8 months of age, and the survival rate after 20 months of age was less than 60%. It can be seen that the survival rate of females in the Zip11- / - generation is higher than that of males.

[0144] Eggs or sperm from male and female zebrafish of different ages (0-3 months old and 6-12 months old) of the F2 generation were in vitro fertilized with sperm or eggs of wild-type zebrafish and cultured. The percentage of fertilized eggs that developed into complete individuals was counted, and the results are shown in Figure 4. From Figure 4, it can be seen that the percentage of fertilized eggs decreased as the age increased, and that male zebrafish of the F2 generation had a lower percentage of fertilized eggs than females.

[0145] Figures 2-4 show that zebrafish lacking Zip11 exhibit aging phenotypes such as spinal curvature, cachexia, reduced regenerative capacity, premature infertility, and shortened lifespan, with aging being more severe in males.

[0146] Example 3: Construction of Zip11 knockout (KO) mice

[0147] Using the principle of homologous recombination, Zip11 KO model mice were constructed for the target gene MGI No. 1917056 or Ensembl No. ENSMUSG00000041654, transcription version ENSMUST00000071539. The embryonic stem cell targeting vector was constructed by Infusion and consisted of a 3.4kb5 homologous arm (5, homologous arm forward primer SEQ ID NO: 5, 5' homologous arm reverse primer SEQ ID NO: 9, 3' homologous arm forward primer SEQ ID NO: 9, 3, homology arm reverse primer SEQ ID NO: 10), a 2.3kb Flox region (SEQ ID NO: 13), PGK-Neo-polyA (SEQ ID NO: 14), a 3.3kb3 homologous arm, and MCl-TK-polyA (SEQ ID NO: 15) negative screening marker, where Flox targets exon 5. Figure 5B shows the plasmid map of the targeting vector. This vector was linearized and introduced into Jm8a3 embryonic stem cells by electroporation. Screening with the drugs G418 and Ganc yielded resistant clones. Positive clones were screened for homologous recombination by long fragment PCR.

[0148] Positive embryonic stem cell clones were amplified and injected into blastocysts of C57BL / 6 mice. The injected blastocysts were then transplanted into the fallopian tubes of surrogate pregnant female mice (C57BL / 6J) according to standard procedures. After birth, the degree of chimerism and whether the mice were chimeric were determined from their fur color, thereby obtaining chimeric mice.

[0149] These chimeric male mice were crossed with Flp mice to obtain F1 generation mice. Neo-containing heterozygous mice were identified by PCR and confirmed by sequencing. Subsequently, the positive F1 heterozygous mice were crossed with Flp mice to obtain F2 generation mice. Neo-heterozygous mice were identified by PCR and confirmed by sequencing. Homologous recombination via Flp yielded target mice with Flox sites at both ends of the Zip11 CKO (Conditional Knockout), i.e., Zip11 allele mice with Flox sites. When Zip11 allele mice with the Flox locus were crossed with tool mice that specifically express Cre recombinase in that tissue, and then the Flox region was knocked out in Flox-purified Cre-positive mice, functional loss of the target gene Zip11 was observed in specific tissues and cell types. This construct is shown in Figure 5A. Figure 5C shows that the KO mice had reduced Zip11 expression and almost no mRNA transcription, indicating that the knockdown was successful.

[0150] Example 4: Phenotyping of the aging state of Zip11 KO mice

[0151] 4.1 Male and female Zip11 KO mice showing signs of hair loss

[0152] The mice were raised in an SPF (Specific Pathogen Free) enclosure and separated into male and female cages 22 days after weaning, where they were allowed to eat and drink freely. The enclosure was maintained at a temperature of 22±3°C, humidity of 35-5%, and a 12-hour day-night cycle. The mice's phenology was regularly monitored.

[0153] Figure 6 shows that Zip11- / - male mice show signs of hair loss at 6 months of age. Figure 7 shows that Zip11 KO female mice show signs of hair loss on both their backs and heads at 8 months of age.

[0154] 4.2 Zip11 mice showing signs of splenomegaly

[0155] Eight-month-old Zip11 knockout mice and wild-type mice were anesthetized and executed. Their spleens and livers were quickly removed, fixed with 4% paraformaldehyde for 48 hours, embedded in paraffin, and dissected at 5 p.m. The tissues were routinely stained with hematoxylin and eosin (H&E), sealed with neutral rubber, and observed under a microscope for tissue changes.

[0156] Figure 8 shows that 8-month-old Zip11 knockout female mice showed signs of splenic hypertrophy compared to wild-type control mice, and that splenic sections showed hypertrophy of the splenic tissue in Zip11 knockout mice (Figure 9).

[0157] 4.3 Zip11 KO mice showed signs of hepatomegaly.

[0158] When sections of mouse liver were observed in the same manner as described above, it was confirmed that the liver tissue of Zip11KO mice was enlarged (Figure 10).

[0159] 4.4 Spontaneous Tumor Formation in Zip11 KO Mice

[0160] Figure 11 shows a photograph of the experimental mouse on the left and an electropherogram of the female experimental mouse on the right, indicating that this mouse is a Zip11 knockout mouse. At 5 months of age, a tumor was observed on the left forelimb of this Zip11 knockout mouse, and a mammary gland tumor was also observed. No spontaneous tumor growth was observed in wild-type control mice in the same cage (Figure 12). As can be seen from Figure 12, tumor growth was significant in the Zip11 KO mouse.

[0161] 4.5 Zip11 KO mice have high levels of inflammatory factors.

[0162] RT-PCR analysis of liver tissue from Zip11- / - mice compared to wild-type mice (Figure 13) revealed elevated mRNA expression levels of inflammatory factors such as IL-6 and TNF-α in Zip11-deficient mice, suggesting a stronger inflammatory response.

[0163] 4.6 Reduced motility in Zip11 KO mice

[0164] The effects of Zip11 on motor function were evaluated using a linear accelerometer (Panlab / Harvard Apparatus, Holliston, USA). Linear accelerometers were attached to Zip11 KO mice and wild-type mice. The rotation speed was increased from 4 rpm to 40 rpm in 300-second cycles. An acceleration protocol was adopted to eliminate the need for adaptation to the tachometer and to minimize the discrepancy in results obtained from each mouse due to imbalances in performance improvement. Each test ended when the mouse fell from the baton swivel, and each mouse underwent three baton swivel acceleration runs on each experimental day, for a total of four experimental days. To prevent performance degradation due to fatigue induction, the animals were allowed to recover for 5 minutes between trials. The time it took for Zip11 KO mice and wild-type mice to fall from the baton swivel was compared.

[0165] The results are shown in Figure 14, indicating that Zip11 KO mice had a shorter time to maintain rotation and weaker motor skills compared to wild-type mice.

[0166] Example 5: Zip11 KO mice induce obesity in male mice.

[0167] A high-fat model was constructed by feeding Zip11 knockout male mice and wild-type mice a high-fat diet (HFD). Three wild-type mice, four Zip11+ / - mice, and four Zip11- / - mice were fed the high-fat diet, and their body weight was measured weekly. The results are shown in Figure 20. Zipir1' male mice were slightly heavier than wild-type mice, indicating that knockout in male mice leads to the appearance of obesity in male mice.

[0168] Example 6: Cognitive and Learning Disorders in Zip11 KO Mice

[0169] After 7 weeks of high-fat conditioning of Zip11 knockout mice, a series of behavioral abilities in the mice (4.5 months old) were probed using open-field experiments. This experiment utilized the avoidance behavior of mice, that is, mice tend to move to the edges of the open field, i.e., near walls, because they fear open and unfamiliar environments, while mice have a natural tendency to explore new environments and explore in the central area. Longer movement time and distance in the central area indicated higher exploratory desire and cognitive ability, while shorter movement time and distance in the central area indicated lower exploratory desire and cognitive ability.

[0170] As described below, knockout male mice (4 Zip11+ / - mice, 4 Zip11- / - mice) and wild-type male mice (3) were each placed in the center of an open-field experimental apparatus. They were allowed to move freely within the apparatus for 15 minutes, and the distance moved in the open field, the distance moved in the center, and the total distance and time moved in the open field were recorded. After each mouse's session, the apparatus was wiped down with 75% alcohol and feces and urine were cleaned to prevent the scent left by the previous mouse from affecting the behavioral performance of the next mouse.

[0171] Figure 21 shows the statistical results of the open-field experiment, and Figure 22 shows the movement trajectories of the mice. In Zip11 knockout mice, the distance and time traveled in the central area were reduced, suggesting decreased exploratory motivation and cognitive ability, and affecting learning and cognitive abilities.

[0172] Example 7: Increase in p53 protein levels in Zip11 KO mice

[0173] Eight-month-old Zip11 male and female knockout mice and their corresponding wild-type mice were anesthetized, tail tissue was rapidly dissected, proteins were extracted from mouse tissue cells, impurities such as cell debris were removed, and p53 protein expression levels were detected by Western blotting. p53 levels were found to be significantly increased in the knockout mice (Figure 23), suggesting that Zip11 knockout is associated with accelerated p53 aging.

[0174] Example 8: Zip11 KO mice with reduced macrophage immune function under LPS stimulation.

[0175] Acute inflammation was induced in wild-type (WT) mice (n=6) and Zip11 KO mice (n=4) by intraperitoneal injection of LPS (2.5 mg / kg) and D-galactosamine (0.25 g / kg). Six hours later, the mice were anesthetized and dissected. Blood and spleen were collected, and labeled anti-CD86 antibody and CD206 antibody were added to each. Flow cytometry was then used to measure the cell ratio of keto-type CD86-positive (M1 macrophages) and CD206-positive (M2 macrophages).

[0176] M1 macrophages exhibit strong pro-inflammatory and antigen-presenting abilities and function in the clearance of host immunity against pathogens and tumor cells. On the other hand, M2 macrophages have anti-inflammatory, wound healing / fibrosis, tissue repair, and tumor growth / invasion promoting effects. As a result, when mice were stimulated with LPS, M1 macrophages decreased significantly (Figure 24A), while M2 macrophages increased significantly, indicating a decrease in the immune function of macrophages (Figure 24B).

[0177] Example 9: Construction of a ZIP11 knock-in mouse model

[0178] The mouse H11 locus is targeted by the construction of an sgRNA (sequences 5, to 3 indicate SEQ ID NO: 2) and a PAM sequence (sequence shown in SEQ ID NO: 3). Based on the sgRNA, a corresponding donor was designed, and a targeting plasmid vector was constructed by inserting the coding region of Zip11, which includes a strong CAG promoter and stop signal flanked by Loxp, and a tdTomato reporter gene linked to human Zip11 with a 2A short peptide. Figure 15A shows the construction of the ZIP 11KI mouse model. The nucleotide sequence of the coding region of human Zip11 (hZip11) is shown in SEQ ID NO: 1.

[0179] Subsequently, this vector was injected into C57BL / 6J embryonic stem cells by microinjection. These blastocysts were transplanted into pseudo-pregnant C57BL / 6J female mice to obtain chimeric mice. The mice born by microinjection were identified by PCR, sequencing, and Southern blotting to obtain positive F0 mice. These F0 mice were individually mated with C57BL / 6J mice, and positive F1 generation mice were obtained by PCR, sequencing, and Southern blotting identification. Next, heterozygous mice were mated with tool mice that specifically express Cre recombinase to obtain H11-ZIP11 knock-in (KI) mice, thereby obtaining pure knock-in mice. After anesthetizing and killing the mice, the livers of ZIP 11 KI mice were rapidly harvested, and the expression level of ZIP mRNA was measured. Figure 15B shows that the hepatic stromal cells of Z7P77KI mice specifically overexpress ZIP 11 compared to wild-type mice, indicating that the knock-in was successful.

[0180] Example 10: Reduction of Zip11 expression by concanavalin A

[0181] Wild-type C57BL / 6 mice were divided into two groups. The experimental group was administered 10 mg / kg of concanavalin (ConA) by tail vein injection. Liver tissue was extracted 18 hours later, and the expression level of ZIP 11 was measured using RT-PCR, with β-actin used as a reference. The results are shown in Figure 16, where ConA reduced ZIP 11 levels.

[0182] Example 11: ZIP11 KI mice are more susceptible to hepatitis reactions induced by concanavalin A.

[0183] Large ZIP11 KI mice at 8 weeks of age and wild-type control mice in the same cage were administered 10 mg / kg of squid protein (ConA) via the tail vein. After 18 hours, the mice were anesthetized, cardiac puncture was performed, and the mice were executed to extract serum. The tissues were fixed with 4% paraformaldehyde, embedded in paraffin, stained with H&E and TUNEL, mounted, and histological changes were observed.

[0184] The concentrations of glutamate oxalyl transaminase (ALT) and glutamate alanine transaminase (AST) in serum were measured. The results are shown in Figures 17 and 18.

[0185] Figure 17A shows a comparison of liver size and color in wild-type and ZIP KI mice in a ConA-induced hepatitis injury model. Figure 17B shows the ratio of liver weight to body weight, and Figures 17C and 17D show elevated serum ALT and AST levels in ZIP 11 KI mice. Figure 18 shows hepatocyte morphology using different staining methods. These results indicate that ZIP 11 KI mice are more susceptible to ConA-induced liver injury.

[0186] Example 12: Reduction of bilirubin levels in ZIP11 KI male mice

[0187] Mice overexpressing ZIP11 in the liver, wild-type 8-week-old male mice, and ZIP11 knockout mice were fed an MCD (Methionine and Choline Deficient L-Amino Acid Diet, i.e., a diet without methionine and choline sources). After 4 weeks, the mice were anesthetized, their livers were dissected, their weight measured, and a series of physiological tests were performed.

[0188] Figure 25A compares the livers of wild-type mice and male mice overexpressing ZIP11. Measurements of serum bilirubin concentrations at the Zhejiang University Drug Safety Evaluation Research Center showed that serum bilirubin levels were significantly reduced in male mice overexpressing ZIP11 liver compared to wild-type mice (Figure 25B), while serum bilirubin levels were significantly increased in ZIP11 knockout male mice compared to wild-type mice (Figures 26A-26C). These findings suggest that ZIP11 plays a protective role in mice given MCD to induce NASH formation.

[0189] Example 13: Vitamins increase Zip11 expression levels.

[0190] Human HEK293 and HT1080 cells were treated with different concentrations of vitamin B3 (10 μM, 50 μM, 100 μM), vitamin B12 (1 μM, 10 μM, 50 μM), and vitamin C (10 μM, 100 μM, 500 μM), respectively, for 24 hours. Relative expression of Zip11 mRNA was detected, and the results are shown in Figure 19. The results showed that the vitamins increased the expression level.

[0191] The detailed description above is provided for illustrative purposes and as an example, and is not intended to limit the scope of the appended claims. Various variations of the embodiments currently enumerated in this application will be obvious to those skilled in the art and will remain within the scope of the appended claims and their equivalents.

Claims

1. 1. A method for identifying a substance capable of affecting aging, said method comprising: determining the effect of candidate substances on Zip11 activity and / or expression and identifying candidate substances that alter the activity and / or expression of Zip11 as substances that affect aging; wherein a candidate substance that increases Zip11 activity and / or expression is identified as a substance that can delay or ameliorate aging; Candidate substances that decrease Zip11 activity and / or expression are identified as substances that may promote or exacerbate aging.

2. determining the effect of the candidate substance on the activity and / or expression of Zip11 comprises determining the effect of the candidate substance on the expression level and / or activity of the Zip11 nucleic acid; determining the level and / or activity of the Zip11 nucleic acid expression using a substance selected from the group consisting of a primer capable of specifically amplifying the Zip11 nucleic acid and a nucleic acid probe capable of specifically recognizing the Zip11 nucleic acid; and / or determining the effect of the candidate substance on the activity and / or expression of Zip11 comprises determining the effect of the candidate substance on the expression level and / or activity of the protein of Zip11; The expression level and / or activity of the Zip11 protein is determined using a substance selected from the group consisting of a reagent that specifically recognizes the Zip11 protein and a substance that can measure the activity of the Zip11 protein. The method of claim 1.

3. the method comprising administering the candidate substance to a non-human animal, organ, tissue and / or cell, determining the effect of the candidate substance on the activity and / or expression of Zip11 in the non-human animal, organ, tissue and / or cell, and identifying a candidate substance that alters the activity and / or expression of Zip11 as a substance that affects aging; and / or The method is an in vitro or ex vivo method, The method according to claim 1 or 2.

4. The aging status is determined by assessing one or more of body morphology, hair status, immune level status, tumor status, liver status, spleen status, fertility status, motor status, life span status, and cognitive status; The body morphology status is evaluated by detecting a spine morphology; The hair condition is assessed by detecting hair loss; The immune status is assessed by detecting cytokine levels; The tumor status is assessed by detecting tumor volume, tumor growth status and / or the presence of tumor cells, and the liver status is assessed by detecting alanine aminotransferase activity, aspartate aminotransferase activity and / or liver / body weight ratio, the spleen status is assessed by measuring the spleen / body weight ratio; said fertility status being assessed by detecting a fertile egg rate; The state of exercise ability is evaluated by a rotarod fatigue test result; The life status is assessed by detecting survival time; and / or The cognitive status is evaluated by an open field test; The method according to any one of claims 1 to 3.

5. A pharmaceutical composition for use in delaying or ameliorating aging, comprising a nucleic acid molecule encoding Zip11 or an expression product thereof.

6. The retardation or amelioration of aging consists of preventing or treating spinal curvature, preventing or treating hair loss, increasing cytokine levels, improving immunity, preventing or treating tumors, extending life span, preventing or treating liver damage, preventing or treating splenic damage, preventing or treating reduced fertility, enhancing athletic performance, delaying the onset of decline in athletic performance and / or enhancing behavioral and cognitive performance; and / or The pharmaceutical composition of claim 5 , wherein the nucleic acid molecule comprises the nucleotide sequence shown in SEQ ID No.

1.

7. A pharmaceutical composition for use in identifying the aging status of a subject, comprising a nucleic acid molecule encoding Zip11 or an expression product thereof.

8. Zip11 activity and / or expression level, comprising Zip11 nucleic acid expression level and / or activity and Zip11 protein expression level and / or activity, is determined to identify the aging status of the subject; measuring the nucleic acid expression level and / or activity of Zip11 in a subject using a substance selected from the group consisting of a primer capable of specifically amplifying a nucleic acid of Zip11 and a nucleic acid probe capable of specifically recognizing the nucleic acid of Zip11; measuring the expression level and / or activity of Zip11 protein in a subject using a substance selected from the group consisting of a reagent that specifically recognizes Zip11 protein and a substance that can measure the activity of Zip11 protein; The aging status is determined by evaluating one or more statuses selected from the group consisting of a body morphology status, a hair status, an immune level status, a tumor status, a liver status, a spleen status, a fertility status, a motor status, a life span status, and a cognitive status; The body morphology status is assessed by detecting spinal morphology; The hair condition is assessed by detecting hair loss; The immune status is assessed by detecting cytokine levels; The state of the tumor is assessed by detecting tumor volume, tumor growth, and / or the presence of tumor cells; said liver status being assessed by detecting alanine aminotransferase activity, aspartate aminotransferase activity and / or liver / body weight ratio; said spleen status being assessed by determining spleen to body weight ratio; The fertility status is evaluated by detecting the fertile egg rate, and the athletic performance status is evaluated by the rotarod fatigue test results. The life status is assessed by detecting survival time; and / or The cognitive status is evaluated by an open field test; The pharmaceutical composition according to claim 7.

9. The agent determining Zip11 activity and / or expression levels is used to distinguish the aging status of a subject.

10. said Zip11 activity and / or expression comprising Zip11 nucleic acid expression level and / or activity, and / or Zip11 protein expression level and / or activity; the substance is characterized in that it comprises a primer capable of amplifying a Zip11 nucleic acid, a nucleic acid probe capable of specifically recognizing a Zip11 nucleic acid, a reagent capable of specifically recognizing a Zip11 protein, and / or a substance capable of measuring the activity of a Zip11 protein; The aging status is determined by assessing one or more of the following group: body morphology, hair status, immune level status, tumor status, liver status, spleen status, fertility status, motor status, lifespan status, and cognitive status; The body morphology is assessed by detecting vertebral morphology; The hair condition is assessed by detecting hair loss; The immune status is assessed by detecting cytokine levels; The state of the tumor is assessed by detecting tumor volume, tumor growth, and / or the presence of tumor cells; said liver status being assessed by detecting alanine aminotransferase activity, aspartate aminotransferase activity and / or liver / body weight ratio; said spleen status being assessed by measuring the spleen / body weight ratio; said fertility status being assessed by measuring fertile egg rate; The state of exercise capacity is evaluated by the results of a rotarod fatigue test; The life status is assessed by detecting survival time; and / or The substance according to claim 9, wherein the cognitive status is assessed by an open field test.

11. A system for identifying the aging state of a subject, comprising a substance capable of measuring the expression and / or activity of Zip11.

12. The system includes a substance capable of measuring the level and / or activity of Zip11 nucleic acid expression, The substance comprises a primer capable of amplifying a nucleic acid of Zip11 and / or a nucleic acid probe capable of specifically identifying a nucleic acid of Zip11; The system includes a substance capable of measuring the expression level and / or activity of Zip11 protein, The substance includes a substance capable of specifically recognizing Zip11 protein and / or a substance capable of measuring Zip11 protein activity, determining the aging status by evaluating one or more selected from the group consisting of body morphology, hair status, immune level status, tumor status, liver status, spleen status, fertility status, motor status, life span status, and cognitive status; The body morphology is assessed by detecting vertebral morphology; The hair condition is assessed by detecting hair loss; The immune status is assessed by detecting cytokine levels. The state of the tumor is assessed by detecting tumor volume, tumor growth, and / or the presence of tumor cells; said liver status being assessed by detecting alanine aminotransferase activity, aspartate aminotransferase activity and / or liver / body weight ratio; said spleen status being assessed by detecting a spleen / body weight ratio; said fertility status being assessed by detecting a fertile egg rate; The state of exercise capacity is evaluated by the results of a rotarod fatigue test; The life status is assessed by detecting survival time; and / or The system of claim 11 , wherein the cognitive status is assessed by an open field test.

13. 1. A method for evaluating the effect of a candidate substance on an aging state in a subject, the method comprising: 1) administering the candidate substance to the subject; 2) comparing the change in Zip11 expression and / or activity in the subject before and after the administration; and 3) evaluating the effect of the candidate substance on the aging state of the subject based on the change in Zip11 expression and / or activity; Here, if the expression and / or activity of Zip11 in the subject increases after administration of the candidate substance, the aging condition in the subject is evaluated as being delayed or improved, and if the expression and / or activity of Zip11 in the subject decreases after administration, the aging condition in the subject is evaluated as being promoted or worsened.

14. said activity and / or expression of Zip11 comprises activity and / or expression at the nucleic acid level of Zip11 and / or activity and / or expression at the protein level of Zip11; The delay or improvement of the aging condition includes preventing or treating spinal curvature, preventing or treating hair loss, increasing cytokine levels, improving immunity, preventing or treating tumors, extending life span, preventing or treating liver damage, preventing or treating splenic damage, preventing or treating decline in fertility, enhancing athletic performance, enhancing behavioral and cognitive performance, and / or delaying the decline in athletic performance; The accelerated or worsening state of aging is characterized by including worsening spinal curvature, worsening hair loss, decreased cytokine levels, decreased immunity, worsening or recurrence of tumors, shortened life span, worsening liver damage, worsening spleen damage, worsening decreased fertility, decreased motor skills, and / or decreased behavioral and cognitive skills. The method of claim 13.

15. A non-human animal or part thereof overexpressing Zip11.

16. Compared to the corresponding wild type, there is an additional copy number of the Zip11 gene, The Zip11 gene is regulated by a tissue-specific promoter; the additional copy number of Zip11 gene is expressed specifically in the liver, The tissue-specific promoter comprises the base sequence shown in SEQ ID NO.1, and / or exhibiting a phenotype in which aging is delayed or improved, A non-human animal or part thereof according to claim 15.

17. The non-human animal or part thereof described in claim 16, characterized in that the delay or improvement of the aging condition includes prevention or treatment of spinal curvature, prevention or treatment of hair loss, increasing cytokine levels, improving immunity, prevention or treatment of tumors, extending lifespan, prevention or treatment of liver damage, prevention or treatment of splenic damage, prevention or treatment of reduced fertility, improvement of motor ability, delay of the time point at which motor ability declines, and / or improvement of behavioral and cognitive abilities.

18. A non-human animal or part thereof in which the expression and / or function of the Zip11 gene is disrupted.

19. At least part of the Zip11 gene has been knocked out. At least a portion of exon 5 of the Zip11 gene is knocked out; exhibiting accelerated or exacerbated aging phenotypes, A non-human animal or part thereof according to claim 18.

20. The non-human animal or part thereof described in claim 19, wherein the accelerated or worsening aging state includes worsening spinal curvature, worsening hair loss, decreased cytokine levels, decreased immunity, worsening or recurrence of tumors, shortened lifespan, worsening liver damage, worsening splenic damage, worsening decreased reproductive ability, decreased motor ability, and decreased behavioral and cognitive ability.